RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX:HBP), (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its collaborator ProMab Biotechnologies, Inc. (“ProMab”) paper entitled ‘CAR-T cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell
Growth’ is published in Cancers – an open access journal (http://www.mdpi.com/journal/cancers).
The paper describes research and validation work on the antibody that the companies are co-developing for a CAR-T application against multiple myeloma. Data described in the paper include in vitro work and proof-of-concept CAR-T animal studies. This paper adds to the recent presentation ProMab has made at the CAR-TCR 2018 Summit in Boston.
20180912-HBP-Press-Release-Collab-ProMab-publication-FINAL.pdf